Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Other Non-Current Liabilities: 2011-2025

Historic Other Non-Current Liabilities for Arrowhead Pharmaceuticals (ARWR) over the last 11 years, with Sep 2025 value amounting to $367.4 million.

  • Arrowhead Pharmaceuticals' Other Non-Current Liabilities rose 7.63% to $367.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $367.4 million, marking a year-over-year increase of 7.63%. This contributed to the annual value of $367.4 million for FY2025, which is 7.63% up from last year.
  • As of FY2025, Arrowhead Pharmaceuticals' Other Non-Current Liabilities stood at $367.4 million, which was up 7.63% from $341.4 million recorded in FY2024.
  • Arrowhead Pharmaceuticals' 5-year Other Non-Current Liabilities high stood at $367.4 million for FY2025, and its period low was $268.3 million during FY2023.
  • In the last 3 years, Arrowhead Pharmaceuticals' Other Non-Current Liabilities had a median value of $341.4 million in 2024 and averaged $325.7 million.
  • Data for Arrowhead Pharmaceuticals' Other Non-Current Liabilities shows a peak YoY grew of 27.22% (in 2024) over the last 5 years.
  • Over the past 3 years, Arrowhead Pharmaceuticals' Other Non-Current Liabilities (Yearly) stood at $268.3 million in 2023, then increased by 27.22% to $341.4 million in 2024, then grew by 7.63% to $367.4 million in 2025.